Security
Galectin Therapeutics Inc. Common Stock · GALT
GALTNASDAQCommon stockCurrentCIK 1133416Updated Oct 14, 2026
Name history
PRO PHARMACEUTICALS INC · through May 26, 2011
GALT price & chart
Loading TradingView…
NASDAQ:GALT on TradingView ↗About the company
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and portal hypertension, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is a…
In the news
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension ↗
Seeking Alpha
Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical ↗
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside ↗
Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript ↗
SEC disclosures
GALECTIN THERAPEUTICS INC files 8-K: Material Event ↗
Recent filings
ARS filing
DEFA14A filing
DEF 14A filing
PRE 14A filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 12,865,000Source | 28,972,000Source | 14,826,000Source | 15,602,000Source | 27,655,000Source | 15,759,000Source | 9,528,000Source | 25,890,000Source | 19,532,000Source | 17,495,000Source | 28,200,000Source | 21,285,000Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,525,000Source | 27,060,000Source | 13,269,000Source | 13,771,000Source | 25,598,000Source | 14,111,000Source | 7,431,000Source | 23,555,000Source | 17,720,000Source | 15,120,000Source | 25,660,000Source | 18,592,000Source |
| Assets, CurrentUSD | 12,729,000Source | 28,666,000Source | 14,659,000Source | 15,427,000Source | 27,287,000Source | 15,691,000Source | 9,285,000Source | 25,460,000Source | 19,436,000Source | 17,252,000Source | 27,710,000Source | 20,552,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,204,000Source | 1,606,000Source | 1,390,000Source | 1,656,000Source | 1,689,000Source | 1,580,000Source | 1,854,000Source | 1,905,000Source | 1,716,000Source | 2,132,000Source | 2,050,000Source | 1,960,000Source |
| Operating Lease, Right-of-Use AssetUSD | 37,000Source | 26,000Source | 118,000Source | 52,000Source | 35,000Source | 6,000Source | 66,000Source | 45,000Source | 22,000Source | 16,000Source | 53,000Source | 86,000Source |
| Other Assets, NoncurrentUSD | 136,000Source | 306,000Source | 167,000Source | 175,000Source | 368,000Source | 68,000Source | 243,000Source | 430,000Source | 96,000Source | 243,000Source | 490,000Source | 733,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 136,445,000Source | 121,453,000Source | 151,678,000Source | 132,769,000Source | 109,802,000Source | 145,996,000Source | 121,789,000Source | 96,976,000Source | 145,727,000Source | 120,565,000Source | 88,441,000Source | 53,479,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 490,000Source | 500,000Source | 480,000Source | 490,000Source | 500,000Source | 480,000Source | 500,000Source | 500,000Source | 490,000Source | 500,000Source | 500,000Source | 510,000Source |
| Common Stock, Value, IssuedUSD | 64,000Source | 62,000Source | 66,000Source | 63,000Source | 62,000Source | 65,000Source | 63,000Source | 61,000Source | 65,000Source | 62,000Source | 61,000Source | 59,000Source |
| Additional Paid in CapitalUSD | 301,127,000Source | 294,776,000Source | 307,667,000Source | 299,318,000Source | 293,872,000Source | 305,108,000Source | 296,630,000Source | 292,499,000Source | 304,073,000Source | 296,217,000Source | 291,847,000Source | 275,081,000Source |
| Retained Earnings (Accumulated Deficit)USD | -426,984,000Source | -389,542,000Source | -446,788,000Source | -418,761,000Source | -378,304,000Source | -437,613,000Source | -411,177,000Source | -365,869,000Source | -432,546,000Source | -401,572,000Source | -354,372,000Source | -309,567,000Source |
| Stockholders' Equity Attributable to ParentUSD | -125,303,000Source | -94,204,000Source | -138,575,000Source | -118,890,000Source | -83,870,000Source | -131,960,000Source | -113,984,000Source | -72,809,000Source | -127,918,000Source | -104,793,000Source | -61,964,000Source | -33,917,000Source |
| Liabilities and EquityUSD | 12,865,000Source | 28,972,000Source | 14,826,000Source | 15,602,000Source | 27,655,000Source | 15,759,000Source | 9,528,000Source | 25,890,000Source | 19,532,000Source | 17,495,000Source | 28,200,000Source | 21,285,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 136,445,000Source | 25,258,000Source | 151,619,000Source | 10,774,000Source | 14,617,000Source | 7,307,000Source | 110,840,000Source | 12,633,000Source | 8,030,000Source | 35,409,000Source | 15,676,000Source | 13,012,000Source |
| Operating Lease, Liability, CurrentUSD | 37,000Source | 32,000Source | 59,000Source | 52,000Source | 44,000Source | 6,000Source | 68,000Source | 48,000Source | 22,000Source | 19,000Source | 46,000Source | 40,000Source |
| Accounts Payable, CurrentUSD | 5,390,000Source | 2,795,000Source | 3,727,000Source | 5,865,000Source | 3,698,000Source | 3,121,000Source | 6,534,000Source | 3,797,000Source | 3,245,000Source | 5,656,000Source | 6,431,000Source | 3,890,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | 7,000Source | — | — | 20,000Source | 66,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 59,000Source | — | 0Source | — | — | 7,000Source | — | 0Source | 20,000Source | 66,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 5,038,000Source | 11,586,000Source | 3,993,000Source | 4,846,000Source | 10,856,000Source | 4,186,000Source | 6,895,000Source | 8,836,000Source | 4,722,000Source | 8,204,000Source | 9,182,000Source | 9,058,000Source |
| Dividends Payable, CurrentUSD | 0Source | 0Source | 62,000Source | 63,000Source | 63,000Source | 0Source | 0Source | 0Source | 63,000Source | 63,000Source | 63,000Source | 64,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortizationUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 686,000Source | 468,000Source | 1,659,000Source | 2,447,000Source | 2,261,000Source | 2,867,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,866,000Source | -7,689,000Source | -23,875,000Source | -41,767,000Source | -32,965,000Source | -31,056,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 257,000Source | 0Source | 26,475,000Source | 31,227,000Source | 40,033,000Source | 10,000,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 11,525,000Source | 27,060,000Source | 13,269,000Source | 13,771,000Source | 14,111,000Source | 7,431,000Source | 17,720,000Source | 15,120,000Source | 25,660,000Source | 18,592,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 498,000Source | 515,000Source | 963,000Source | 500,000Source | 775,000Source | 468,000Source | 1,656,000Source | 2,447,000Source | 2,261,000Source | 2,867,000Source |
| Dividends Payable, CurrentUSD | — | — | 0Source | 0Source | 62,000Source | 63,000Source | 0Source | 0Source | 63,000Source | 63,000Source | 63,000Source | 64,000Source |
| General and Administrative ExpenseUSD | — | — | 1,587,000Source | 1,471,000Source | 1,847,000Source | 1,364,000Source | 1,846,000Source | 1,412,000Source | 5,795,000Source | 5,862,000Source | 5,942,000Source | 6,615,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 1,820,000Source | 1,494,000Source | 2,004,000Source | 1,826,000Source | 1,988,000Source | 1,744,000Source | 7,329,000Source | 5,540,000Source | — | — |
| Investment Income, InterestUSD | — | — | 39,000Source | 93,000Source | 28,000Source | 26,000Source | 36,000Source | 35,000Source | 126,000Source | 338,000Source | 230,000Source | 52,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,184,000Source | -11,220,000Source | -9,113,000Source | -7,521,000Source | -5,046,000Source | -9,631,000Source | -30,836,000Source | -47,047,000Source | -41,066,000Source | -38,776,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -8,223,000Source | -11,238,000Source | -9,175,000Source | -7,584,000Source | -5,067,000Source | -9,605,000Source | -30,974,000Source | -47,200,000Source | -44,805,000Source | -38,873,000Source |
| Nonoperating Income (Expense)USD | — | — | -3,986,000Source | -2,154,000Source | -5,131,000Source | -2,896,000Source | -969,000Source | -1,734,000Source | -10,751,000Source | -4,614,000Source | -2,994,000Source | -424,000Source |
| Operating ExpensesUSD | — | — | 4,198,000Source | 9,066,000Source | 3,982,000Source | 4,625,000Source | 4,077,000Source | 7,897,000Source | 20,085,000Source | 42,433,000Source | 38,072,000Source | 38,352,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 3,235,000Source | — | — | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -4,198,000Source | -9,066,000Source | -3,982,000Source | -4,625,000Source | -4,077,000Source | -7,897,000Source | -20,085,000Source | -42,433,000Source | -38,072,000Source | -38,352,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -8,184,000Source | -11,220,000Source | -9,113,000Source | -7,521,000Source | -5,046,000Source | -9,631,000Source | -30,836,000Source | -47,047,000Source | -41,066,000Source | -38,776,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.13Source | -0.18Source | -0.14Source | -0.12Source | -0.08Source | -0.15Source | -0.48Source | -0.76Source | -0.74Source | -0.65Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.13Source | -0.18Source | -0.14Source | -0.12Source | -0.08Source | -0.15Source | -0.48Source | -0.76Source | -0.74Source | -0.65Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 64,205,000Source | 62,278,000Source | 65,875,000Source | 63,447,000Source | 65,782,000Source | 63,204,000Source | 63,903,000Source | 62,309,000Source | 60,159,000Source | 59,391,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 64,205,000Source | 62,278,000Source | 65,875,000Source | 63,447,000Source | 65,782,000Source | 63,204,000Source | 63,903,000Source | 62,309,000Source | 60,159,000Source | 59,391,000Source |
| Interest Expense (non-operating)USD | — | — | 1,820,000Source | 1,494,000Source | 2,004,000Source | 1,826,000Source | 1,988,000Source | 1,744,000Source | 7,329,000Source | 5,540,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 1,587,000Source | 1,471,000Source | 1,847,000Source | 1,364,000Source | 1,846,000Source | 1,412,000Source | 5,795,000Source | 5,862,000Source | 5,942,000Source | 6,615,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 2,792,000Source | 1,033,000Source |
| Investment Income, InterestUSD | — | — | 39,000Source | 93,000Source | 28,000Source | 26,000Source | 36,000Source | 35,000Source | 126,000Source | 338,000Source | 230,000Source | 52,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -8,223,000Source | -11,238,000Source | -9,175,000Source | -7,584,000Source | -5,067,000Source | -9,605,000Source | -30,974,000Source | -47,200,000Source | -44,805,000Source | -38,873,000Source |
| Nonoperating Income (Expense)USD | — | — | -3,986,000Source | -2,154,000Source | -5,131,000Source | -2,896,000Source | -969,000Source | -1,734,000Source | -10,751,000Source | -4,614,000Source | -2,994,000Source | -424,000Source |
| Operating ExpensesUSD | — | — | 4,198,000Source | 9,066,000Source | 3,982,000Source | 4,625,000Source | 4,077,000Source | 7,897,000Source | 20,085,000Source | 42,433,000Source | 38,072,000Source | 38,352,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | 39,000Source | 18,000Source | 62,000Source | 63,000Source | 21,000Source | -26,000Source | 138,000Source | 153,000Source | 120,000Source | — |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | — | — | — | — | — | — | — | 97,000Source |
| Research and Development ExpenseUSD | — | — | 2,611,000Source | 7,595,000Source | 2,135,000Source | 3,261,000Source | 2,231,000Source | 6,485,000Source | 14,290,000Source | 36,571,000Source | 32,130,000Source | 31,737,000Source |
Offerings
Registration 333-294782
Filing attachments
ef20080011_ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ef20080011_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026. “We had a very productive second quarter. Importantly, we reached an agreem…
Read attachment ↗ef20079045_ex99-1.htm · 8-K · 2026-08-04
EX-99.1 5 ef20079045_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga., August 4, 2026 (GLOBE NEWSWIRE) - - Galectin Therapeutics Inc. (NASDAQ: GALT) ("Galectin"…
Read attachment ↗ef20076593_ex99-1.htm · 8-K · 2026-06-23
EX-99.1 2 ef20076593_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectin Company intends to file the Phase 3 protocol in Q3 2026 and is actively exploring strategic and financial partnership opportunities to support the co…
Read attachment ↗ef20073003_ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ef20073003_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026. “We continue to make meaningful progress advancing the belapectin program an…
Read attachment ↗ny20068655x1_ex107.htm · S-3 · 2026-03-31
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Galectin Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of…
Read attachment ↗ef20068722_ex99-1.htm · 8-K · 2026-03-31
EX-99.1 2 ef20068722_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are …
Read attachment ↗